Meningococcal serogroup B vaccines: Estimating breadth of coverage

Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains

(2017) Shannon L. Harris et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution

(2016) Stephen A. Clark et al.   JOURNAL OF INFECTION

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak

(2016) Nicole E. Basta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine

(2016) Shelly Senders et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention

(2016) Bruce Atkinson et al.   PHARMACOTHERAPY

A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt

(2016) Olivier Manigart et al.   PLoS One

Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®)

(2016) Ashesh Gandhi et al.   POSTGRADUATE MEDICINE

Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined

(2016) Massimiliano Biagini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers

(2016) David M. Reiner et al.   VACCINE

Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents

(2016) Timo Vesikari et al.   Journal of the Pediatric Infectious Diseases Society

Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine

(2015) Raffaella Rossi et al.   Clinical and Vaccine Immunology

A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013

(2015) L O’Connor et al.   Eurosurveillance

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine

(2015) Duccio Medini et al.   VACCINE

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes

(2015) Alexander Domnich et al.   Journal of Immunology Research

Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015

(2015) Jessica R. MacNeil et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

(2015) Timo Vesikari et al.   Journal of the Pediatric Infectious Diseases Society

Four-month outbreak of invasive meningococcal disease caused by a rare serogroup B strain, identified through the use of molecular PorA subtyping, England, 2013

(2014) C Chatt et al.   Eurosurveillance

The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease

(2014) Gary W Zlotnick et al.   Human Vaccines & Immunotherapeutics

A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups

(2013) Susan K. Hoiseth et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

(2013) Helen S. Marshall et al.   VACCINE

A cluster of four cases of meningococcal disease in a single nuclear family

(2012) P Acheson et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

(2012) Peter C Richmond et al.   LANCET INFECTIOUS DISEASES

Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study

(2012) Russell M Viner et al.   LANCET NEUROLOGY

A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents

(2012) Michael D. Nissen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Meningococcal disease: Clinical presentation and sequelae

(2012) David Pace et al.   VACCINE

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial

(2012) P.C. Richmond et al.   VACCINE

History of meningococcal vaccines and their serological correlates of protection

(2012) Caroline Vipond et al.   VACCINE

Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic

(2011) Diana Lennon et al.   JOURNAL OF PAEDIATRICS AND CHILD HEALTH

Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source

(2011) C.J. Gill et al.   VACCINE

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide

(2009) Lisa K. McNeil et al.   VACCINE